ArticleEye (London, England)2025
Prevalence of pediatric and adult optic neuritis in the United States from 2016 to 2023.
Article in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Pharmacovigilance analysis of immune checkpoint inhibitor-associated optic nerve toxicity based on the FAERS database.Frontiers in pharmacology · 2026Article
- Age inaccuracies in an epidemiological study of paediatric and adult optic neuritis.Eye (London, England) · 2025Article
- Public health implications of delayed diagnosis and treatment of optic neuritis in low-resource settings: a retrospective study of visual recovery outcomes.Frontiers in ophthalmology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND/
objectivesData on the prevalence of optic neuritis (ON) is limited with reported rates between 5.5 and 115.3 per 100,000. The US data is even more limited with the largest study performed in a single county, finding a prevalence of 115.3. This study aims to fill the gap in US data on ON.
methodsThis (2016-2023) cross-sectional study included patients with ICD-10 codes of retrobulbar neuritis, other ON, unspecified ON, and excluded those with optic papillitis, nutritional optic neuropathy, toxic optic neuropathy. Data was collected through a series of queries in a large platform (TriNetX, LLC) containing EHR data from over 113 million patients.
resultsIn 2023, the prevalence of ON was 51.6 per 100,000 people in the overall population. Females had a 1.31 (95% CI, 1.27-1.36) increased odds of disease compared to males. Investigating racial and ethnic breakdown, the highest prevalence was found in the Black population (57.8/100,000) (OR 1.06 (1.01-1.10)), followed by the White (54.7/100,000) (REF) and then Hispanic or Latino populations (45.8/100,000) (OR 0.84 (0.79-0.89)) in 2023. Stratified by age, those ages 45-54 had the highest prevalence (71.3/100,000). The prevalence of ON increased 1.08 (1.05-1.10) times from 2016-2023, with the greatest increase seen in the Hispanic population. Significant increases in prevalence were also seen in the 0-14, 15-24, and 25-34 age groups. DISCUSSION: Racial, ethnic and sex disparities are apparent in the distribution of ON, with Black individuals and females affected most often, and an increasing prevalence seen in the Hispanic population. Younger subpopulations also demonstrated significant increases, warranting additional investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.